<DOC>
	<DOCNO>NCT01899755</DOCNO>
	<brief_summary>GSK2800528 develop human anti-tumor necrosis factor ( TNF ) alpha monoclonal antibody ( mAb ) treatment immune-inflammatory disease . The study conduct healthy volunteer divide 4 cohort . Cohorts 1 3 consist group 12 subject , 9 active treatment ( GSK2800528 ) , 3 placebo . Cohort 4 consist group 9 subject , active treatment ( adalimumab ) .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics ( PK ) , Safety Tolerability , Immunogenicity , Pharmacodynamics ( PD ) GSK2800528 Healthy Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>ALT , alkaline phosphatase bilirubin &lt; = 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Average bazett 's correct QT interval ( QTcB ) &lt; 450 msec , QTcB &lt; 480 msec subject Bundle Branch Block . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include investigator 's discretion provide find unlikely introduce additional risk factor , jeopardize study integrity , interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 21.7 international unit/liter ( IU/L ) oestradiol &lt; 110 picomoles/liter ( pmol/L ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method specify study protocol . Male subject female partner childbearing potential must agree use one contraception method specify study protocol . Body weight &gt; = 60 kg body mass index ( BMI ) within range 19 31 kilogram/meter2 ( kg/m2 ) ( inclusive ) . A positive prestudy Quantiferon test , Hepatitis B surface antigen , positive Hepatitis C antibody result within 3 month screen . Current chronic history liver kidney disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Previous treatment adalimumab . Current , history , cancer . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Travel region high endemic tuberculosis/infection , judge investigator medical monitor , prohibit start screen final follow visit . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Current evidence history bacterial , viral , fungal infection within 7 day dose . Subject receive type vaccination within 21 day dose require vaccination prior end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>TNF alpha</keyword>
</DOC>